ArticlePituitary2022
Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States.
Article in Pituitary, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Acromegaly and breast cancer risk: evidence from a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Co-secretion of growth hormone and prolactin defines a high-risk acromegaly phenotype.Pituitary · 2026Article
- Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly.Pituitary · 2025Article
- Management of acromegaly beyond primary surgery: efficacy and safety of repeat surgery and radiotherapy.Acta neurochirurgica · 2025Article
- GIP Receptor Antagonism Eliminates Paradoxical Growth Hormone Secretion in Some Patients With Acromegaly.The Journal of clinical endocrinology and metabolism · 2025Article
- Patient perspectives on acromegaly disease burden: insights from a community meeting.Frontiers in endocrinology · 2025Article
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Acromegaly and COVID-19, lessons, and new opportunities.Pituitary · 2024Article
- Article
- Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis.Pituitary · 2024Observational
- Multidisciplinary Team Care in Pituitary Tumours.Cancers · 2024Review
- Evidence of shared genetic factors in the etiology of gastrointestinal disorders and endometriosis and clinical implications for disease management.Cell reports. Medicine · 2023Article
- Incidence and risk factors of cancers in acromegaly: a Chinese single-center retrospective study.Endocrine · 2023Article
- The Relationship between the Burden of Acromegaly, Associated Comorbidities, Complications and Disease Status.Journal of clinical medicine · 2023Article
- Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis.Journal of the Endocrine Society · 2023Article
- Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas.International journal of molecular sciences · 2023Review
- Article
- Adherence to Acromegaly Treatment and Analysis of the Related Factors-A Real-World Study in Bulgaria.Pharmaceutics · 2023Article
- Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients receiving treatment for acromegaly often experience significant associated comorbidities for which they are prescribed additional medications. We aimed to determine the real-world prevalence of comorbidities and concomitant medications in patients with acromegaly, and to investigate the association between frequency of comorbidities and number of concomitantly prescribed medications.
methodsAdministrative claims data were obtained from the IBM® MarketScan® database for a cohort of patients with acromegaly, identified by relevant diagnosis codes and acromegaly treatments, and a matched control cohort of patients without acromegaly from January 2010 through April 2020. Comorbidities were identified based on relevant claims and assessed for both cohorts.
resultsOverall, 1175 patients with acromegaly and 5875 matched patients without acromegaly were included. Patients with acromegaly had significantly more comorbidities and were prescribed concomitant medications more so than patients without acromegaly. In the acromegaly and control cohorts, respectively, 67.6% and 48.4% of patients had cardiovascular disorders, the most prevalent comorbidities, and 89.0% and 68.3% were prescribed > 3 concomitant medications (p < 0.0001). Hypopituitarism and hypothalamic disorders, sleep apnea, malignant neoplasms and cancer, and arthritis and musculoskeletal disorders were also highly prevalent in the acromegaly cohort. A moderate, positive correlation (Spearman correlation coefficient 0.60) was found between number of comorbidities and number of concomitant medications in the acromegaly cohort.
conclusionCompared with patients without acromegaly, patients with acromegaly have significantly more comorbidities and are prescribed significantly more concomitant medications. Physicians should consider the number and type of ongoing medications for individual patients before prescribing additional acromegaly treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.